Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 5%; BSE HEALTHCARE Index Down 0.1%
Tue, 1 Oct 9:35

Panacea Biotech Gains 5%; BSE HEALTHCARE Index Down 0.1%Image source: Eoneren/www.istockphoto.com

Panacea Biotech share price has zoomed 5% and is presently trading at Rs 316.0.

Meanwhile, the BSE HEALTHCARE index is at 44,202.3 (down 0.1%).

Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 6.4%) and Pfizer (up 1.2%).

ASTRAZENECA PHARMA (down 2.3%) and ALEMBIC PHARMA (down 0.9%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 159.5 to Rs 316.0, registering a gain of Rs 156.5 (up 98.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,071.8 to 44,202.3, registering a gain of 57.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 171.2%), SUVEN PHARMACEUTICALS (up 117.9%) and Glenmark Pharma (up 114.6%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 84,555.0 (up 0.3%).

The top gainers among the BSE Sensex today are Tech Mahindra (up 3.3%) and M&M (up 1.1%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 25,810.9 (down 1.4%). Hero Motocorp and Reliance Ind. are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,118.7 to 84,555.0, registering a gain of 18,436.3 points (up 27.9%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -68.2.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 5%; BSE HEALTHCARE Index Down 0.1%". Click here!